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one that a new technology having the ICER smaller than L0 should not be accepted 
if the incremental effectiveness of the new technology is greater than the amount 
of Bmax divided by N times Lk. On the contrary, although the new technology can-
not be accepted (i.e., Lk > L0) under the conventional single-threshold approach, it 
should be accepted if the incremental effectiveness of the new technology is smaller 
than the amount of Bmax divided by N times Lk. ConClusions: Our approach 
offers multiple decision criteria for assessing a new health care technology with 
respect to the cost-effectiveness and its acceptability under the budget constraint. 
The theory which links single-ICER decision with budget impact has a potential 
to improve value-based decision making in government based on price-volume 
consideration of a new technology.
PRM37
Methods foR evaluation of Medical devices
Thokala P.
University of Sheffield, Sheffield, UK
PurPose: Evaluation of medical devices faces different challenges to that of the 
pharmaceutical drugs i.e., the approaches for cost-effectiveness modelling of phar-
maceutical drugs are not suitable for evaluation of devices. For example, the value 
of a device goes beyond the health benefits (i.e QALYs) to the patient as it might 
include other aspects such as increased efficiency, patient dignity, etc. Similarly, 
traditional cost modelling techniques are not suitable for evaluation of devices. 
The costs are not evenly spread across time and depend on implementation strate-
gies (i.e. parameters such as volume, scale, etc) and there is a need for a modelling 
framework that can output time profile of costs by stakeholder. Furthermore, the 
cost-effectiveness depends on the service setting (i.e. parameters such as volume 
and scale of deployment). Method: This presentation describes the lessons learnt 
while evlauating the cost-effectivess of diagnostic tests and devices. The details of 
the different projects are as follows a) Finanical modelling of telemonitoring for 
HF and COPD, b) Cost effectiveness of Cardiac Magnetic Resonance imaging for 
ischaemic cardiomyopathy, c) Cost-effectiveness of Telemonitoring technologies for 
congestive heart failure. result: A brief description of the context that makes HTA 
of medical devices of interest and characteristics of the devices that make them dif-
ferent from pharmaceutical drugs is detailed. An overview of current approaches of 
evaluating devices at different HTA bodies is provided. A taxonomy to represent the 
value of medical devices along with methods for incorporating patients’ preferences 
with examples of specific case studies. Finally, a financial modelling framework for 
evaluating devices that provides time profile of costs by stakeholder. ConClusion: 
Cost-effectiveness evaluation of medical devices is quite different to that of phar-
maceutical drugs. An overview of current methods for evaluation of devices and 
the issues involved are described along with a tentative  framework proposal for 
cost-effectiveness modelling of devices.
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Methods of a survey research in health have recently been included in an ethical 
review board in Thailand. A main goal of ethical consideration in health research 
is to protect the right and well-being of research participants, i.e., patients, villag-
ers and residents and to ensure the right and freedom of the research participants 
to corporate in a provision of research information.  The objective of this paper is 
to discuss loopholes of research methods in health and the discussions derived in 
part from a review board. A careful procedure of research methodology indicates 
the quality of research findings and provides a clue to the answer whether the 
results of research could be able for policy practices.  Methods ensure how health 
researchers are able to conduct the proper activities in seeking more truly research 
information from the participants . And the ethical review is to be certain how the 
personal information of the participants should be kept carefully. Loopholes in 
methods of health research were definitely lowering the quality of research prod-
ucts. Importantly, an application of research became questionable. Many loopholes 
were found in various steps of methodological application, including, setting an 
inclusion criteria, conducting an interview, utilizing research tool and more on 
stating research objectives and making a research title. The inclusion criteria of 
the research participants was specifically not inclusive, an interview usually held 
in hastezy environments  and improper mechanism for field research. Research 
tools applied were not carefully constructed and culturally inappropriate to the 
research subjects. Presenting a research protocol showed several inadequate train-
ing in methodological practices.
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Endothelium-dependent hyperpolarizations and relaxation of vascular smooth 
muscle induced by acetylcholine and bradykinin are mediated by endothelium-
derived hyperpolarizing factors (EDHFs). Arachidonic acid is metabolizedby 
cytochrome-P450 (CYP450) to four regioisomeric epoxyeicosatrienoic acids (EETs) 
that function as EDHFs.  5,6-, 8,9-, 11,12- and 14,15-EET are equipotent in relaxing 
bovine coronary arteries (BCAs). The miconazole analog, WX-III-287-19 was synthe-
sized and compared to EETsin causing relaxations of BCAs. EETs vascular relaxation 
responses were recorded using isometric tension recording.  BCA metabolism of 
20-H-11,12-EE8ZE was analyzed by mass spectrometry. In U-46619-preconstricted 
arterial rings, WX-III-287-19 caused concentration-dependent relaxation with 
maximal relaxation ranging from 95-100%; however, relaxations by 5,6-8,9-11,12 
and 14,15 EETs were less than WX-III-287-19. Preincubation of arteries with the 
a new part in terms of existing questionnaires – evaluates the homogeneity of 
the reported results and statistical methods, which are extremely important in 
preparing health technology assessment reports. At the moment the validation of 
developed scale is in progress – the results of evaluation will be presented at the 
conference. ConClusions: Improving standards of quality assessment of obser-
vational studies using the developed questionnaire, SQAROS, will help to obtain 
from these trials valuable scientific data on the effectiveness of health technologies.
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objeCtives: Evidence from real world are important for patients care. Pragmatic 
randomized control trial (PRCT) as one of the research methods of Comparative 
Effectiveness Research (CER) is used in many medical fields recently. This study 
aims to assess design and reporting qualities of PRCTs published in joint replace-
ment fields. Methods: We searched the Medline, Embase, CENTRAL to February 
2014 and the reference lists of retrieved studies to identify the full-report pragmatic 
randomized trials in English that compared Total Hip Replacement (THR) or Total 
Knee Replacement (TKR) with a conventional treatment. Three reviewers indepen-
dently assess the quality of PRCTs by using the pragmatic-explanatory continuum 
indicator summary (PRECIS) tool, CONSORT statement guidelines and the six CER 
defining characteristics of the Institute of Medicine (IOM). results: We screened 
55 potentially eligible abstracts and identified 6 full-text  PRCTs of joint replacement 
fields. Finally 3 trials with 4,152 patients were assessed. Three reviewers scored the 3 
trials based on PRECIS tool (39.5 vs 44 vs 36); CONSORT statement guidelines (36.5 vs 
39 vs 37.5); IOM defining characteristics of CER (26.5 vs 29 vs 29). All 3 trials reported 
the clinical, economic and patient-centered outcomes. The Knee Arthroplasty Trial 
with 10 years’ follow-up was scored the highest and considered to be more closer 
to the real world than other two trials as it was conducted in 2352 patients from 34 
UK centers and 116 surgeons in the study could adjusted their treatments based on 
individual patients’ characteristics. ConClusions: PRCT is different from stand-
ard RCT in many aspects. The number of PRCT in joint replacement field is limited 
and the quality need to be improved. PRECIS, CONSORT guidelines are useful for 
researchers in designing and reporting the PRCT.
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objeCtives: To determine the best algorithm for using the GRACE checklist to 
rate the quality of observational comparative effectiveness research (CER) stud-
ies. Methods: An 11-item checklist about data and methods was developed 
through literature review and consultation with experts. The checklist was applied 
to 88 articles by 113 raters from 5 continents, and their feedback helped shape 
questions and user guidance. Positive and negative predictive values (PPV and NPV, 
respectively) were calculated based on a volunteer rater’s assessment of a published 
article compared to a “gold standard” as determined through an article’s inclusion in 
a systematic review or through expert assessment. Multivariate regression analysis 
and Classification and Regression Trees (CART) analysis will be conducted based on 
data collected from 22 volunteer raters’ assessment of 28 articles of comparative 
effectiveness using a revised version of the checklist. results: Checklist items 
pertaining to data have relatively strong NPV, meaning the checklist is effective 
in identifying CER articles of insufficient quality. The single best performing item 
was the validity of the primary outcome, which achieved NPV and PPV ≥ 0.67 in 
four rounds of testing. Question items pertaining to whether the primary outcome 
was measured objectively and adequately recorded also achieved high NPV (≥ 0.67 
in 4 and 5 rounds of testing, respectively). Other indicators of quality include the 
use of concurrent comparators (NPV ≥ 0.67 in 5 rounds of testing). ConClusions: 
Univariate analyses have demonstrated the usefulness of the checklist items to 
screen out articles of insufficient quality for decision support. Results of multi-
variate analyses as used to develop 1) a parsimonious model to identify which 
checklist items can best be used as a quick screening tool and 2) a regression tree 
that maximizes the NPV of the checklist will be presented.
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objeCtives: To develop multiple decision criteria for assessing cost-effectiveness 
of a new health care technology under the budget constraint often experienced in 
government managing the national health insurance system. Methods: Let Lk, 
L0, Bmax, and N be, respectively, the ICER of a new technology compared to its com-
parator, the cost-effectiveness threshold for acceptance of any new technology on 
reimbursement decision, maximal increment of the government budget caused by 
the new technology, and the population-size targeted for the new technology. Based 
on those parameters, the mathematical relations among them were theoretically 
developed, formulated and graphically represented on the 2-dimensional plane of 
incremental cost and effectiveness. results: The single-threshold decision mak-
ing defined in pharmacoeconomics is that the ICER, Lk, of a new technology can 
be accepted if and only if Lk is smaller than the pre-defined ICER threshold, L0. We 
proved, however, this conventional decision should be changed into more complex 
